Do I Need Product Liability Insurance Before FDA Clearance?

Probably, but the trigger is not clearance. Product liability exposure begins the first time your device touches a human or leaves your control, and both of those moments often arrive well before a 510(k) clearance or a PMA approval. Treating clearance as the starting line is how companies end up with a gap during the riskiest phase of their early life.

Clearance Is Not the Coverage Trigger

A regulatory clearance tells the market the device met a standard. It says nothing about when your liability begins. Liability attaches to use and to distribution. If a person uses the device, or if the device leaves your hands and moves down a supply chain, the exposure exists whether or not a clearance letter has arrived. The two questions that actually open exposure are simple. Has anyone used the device, and has the device left your control. If the answer to either is yes, the exposure is live. Founders often assume that no clearance means no product on the market and therefore no risk, and the investigational phase breaks that assumption, because devices are used on people long before they are cleared. The clearance milestone matters for marketing and reimbursement, but it is the wrong event to anchor an insurance program to.

Before Human Use: What You Actually Carry

The exposure before clearance usually runs through clinical studies rather than commercial sales. A device used in a clinical trial or a 510(k) review-phase study creates a real bodily-injury exposure, and the coverage that responds is clinical trial liability, arranged before the first subject is enrolled. Clinical trial liability and product liability are not the same line, and a policy built for one does not automatically answer for the other. If your device is still on the bench with no human contact, your product exposure is genuinely low, but it is rarely zero, because suppliers, contract manufacturers, and early partners all sit in a chain that a claim can reach. If you operate from home, do not rely on a personal policy, because a homeowners policy excludes your device startup.

Why Contracts Force the Question Early

Even when the injury risk is low, the paperwork tends to require coverage well before clearance. A contract manufacturer will ask to be named as an additional insured. A clinical site or an academic medical center will require evidence of coverage before it runs a study. Investors examine the program during diligence and expect to see that the exposure is handled. A commercial lease, a distributor agreement, or a supplier contract can each carry an insurance requirement. Each of these requirements has its own date, and those dates rarely line up with the clearance you are waiting on. In practice these obligations, not the FDA timeline, are what put product and related liability coverage on the calendar.

What to Do Before Clearance

Do not wait for the clearance letter to arrange coverage. Underwriting a device program takes time, and the worst moment to discover a gap is the day a study starts or the first unit ships. At the earliest stage, the minimum viable program is mapped in seed-stage life sciences insurance. Map your real timeline, first human use, first shipment, and the contract dates that demand evidence of insurance, then place coverage to those dates. A short call with a broker who places device programs will tell you which lines need to bind first and which can wait, so you are not paying for coverage ahead of the exposure or scrambling to add it the week a study opens. As the device moves toward launch, the program also has to expand from study coverage into a full products liability program, and a bundled small-business policy will not carry that load, as covered in why a standard BOP does not cover a Class II device. Coverage timing is not only about the product; once there is a board or outside capital, a device company also needs D&O for its leadership.

Before clearance, have your exposure mapped against first human use and first distribution rather than against the FDA calendar. A specialty review through Tower Street Insurance can line your coverage up with the dates that actually create risk.